In the early 2000s, a new era of clinical research began – the digital era. As large sponsors and CROs like IQVIA andGlaxo Smith Kline began implementing electronic data capture (EDC) systems into their trials, clinical trial sites experienced the first major digital disruption in how they conducted clinical research. Fast forward totoday, and this cycle of disruption not only continues, it’s shortened.

As a recent article by BusinessInsider states, “it took 30 years forelectricity to be adopted by 10% ofUS consumers. It took 25 years for the telephone to achieve the same penetration. Tablets achieved thisreach in just five years – and they’re not even our primary devices." This shortened cycle of mass adoption has brought smartphones,smartwatches, tablets, and moreto trials, as well as new software and portal applications like eCOA and eConsent. However, it’s been reported that too much technology is commonplace and it quickly overwhelms.

In this white paper, we’ll examine best practices in ensuring sites are adequately prepared and supported for new trial technologies,derived from the experiences of key individuals with direct experience from pharma, technology vendors and importantly from sites themselves.

‍

‍

It’s impossible to deny how different clinical trials look almost four years after the pandemic revolutionized clinical research. Today, the digital and decentralized tools and technologies that enabled clinical trials to carry on through the COVID-19 pandemic are present (in some form) in nearly all clinical trials, a far cry from the dynamics of 2019.

A top 10 pharmaceutical company approached Medable seeking support for their Phase III diabetes study in the highly competitive weight loss market. Their primary goal was toreduce the client’s average study build timelines from 16-20 weeks, down to just 8 weeks,a reduction of more than 50%.

‍

See how Medable was able to meet the customer's goal with this case study.